D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1.
Jacques Corbeil,Louise Evans,P. W. McQueen,Eva Vasak,Paul D Edward,Douglas D. Richman,Ronald Penny,David A. Cooper +7 more
TL;DR: The results confirm that non‐CD4 expressing cells, such as endothelial cells and certain colon epithelial cells, serve as targets and reservoirs for HIV and the production of IL‐6 by HIV‐infected endothelial Cells may be a contributing factor to the aberrant immunoregulation associated with HIV infection in vivo.
Journal ArticleDOI
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
Reshma Saskia Autar,Jintanat Ananworanich,Wichitra Apateerapong,Jongkol Sankote,Andrew Hill,Bernard Hirschel,David A. Cooper,Joep M. A. Lange,Praphan Phanuphak,Ruxrungtham K,Danielle Burger +10 more
TL;DR: A pharmacokinetic comparison of three dosing regimens of saquinavir/ritonavir found dosage of 2000/100 mg once- daily may be preferred, taking the convenience of once-daily dosing into consideration.
Journal ArticleDOI
No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001.
Palanee Ammaranond,Philip Cunningham,Robert Oelrichs,Kazuo Suzuki,Claire Harris,Leakhena Leas,Andrew E. Grulich,David A. Cooper,Anthony D. Kelleher +8 more
TL;DR: Rates of resistance to reverse transcriptase inhibitors peaked in the mid-1990s, fell dramatically with the introduction of combination therapy and appear to have plateaued at 10-15% over the past 3 years.
Journal ArticleDOI
Effects of IL‐2 therapy in asymptomatic HIV‐infected individuals on proliferative responses to mitogens, recall antigens and HIV‐related antigens
Anthony D. Kelleher,Monika Roggensack,Sean Emery,Andrew Carr,Martyn A. French,David A. Cooper +5 more
TL;DR: IL‐2 therapy results in a significant increase in peripheral blood CD4+ lymphocyte count, but this increase is not associated with quantifiable improvements in lymphoproliferative responses to mitogens, recall or HIV antigens.
Journal ArticleDOI
Suppression of antigen-specific lymphocyte activation in modeled microgravity
TL;DR: It is confirmed that the suppression of activation observed with polyclonal models also encompasses oligoclonal antigen-specific activation, and use of isolated immune cells in true and modeled microgravity in immune performance tests, suggests a direct effect of microgravity on in vitro cellular function.